List view / Grid view
16 October 2013 | By Sanofi
Alirocumab monotherapy reduced “bad” cholesterol three times more than ezetimibe...
16 October 2013 | By Novo Nordisk
“The approval of Novoeight® marks an important step in offering a new alternative for people with haemophilia A..."
16 October 2013 | By Gilead
Long-term data in treatment-naïve patients highlight Stribild’s sustained efficacy, safety and tolerability profile...
16 October 2013 | By Amgen
Mr. Garland will serve on the Governance and Nominating Committee and the Audit Committee of the Board...
15 October 2013 | By Johnson & Johnson
...for a fixed-dose combination tablet of HIV-1 medicine Darunavir with Cobicistat...
15 October 2013 | By AstraZeneca
Additional investment in and collaboration with ADC Therapeutics...
14 October 2013 | By Boehringer Ingelheim
Nintedanib*, when added to chemotherapy, is the first lung cancer treatment that extended patient survival...
14 October 2013 | By Roche
Investment to help meet rising demand for licensed biologics and expected pipeline growth...
14 October 2013 | By H. Lundbeck A/S
The Michael J. Fox Foundation has donated 5.5 million kroner to two Danish research projects in Parkinson's disease...
11 October 2013 | By Abbott
"Malnutrition in children is associated with poor health outcomes and this is especially important in the hospitalized child..."
11 October 2013 | By AstraZeneca
AstraZeneca announced that it has entered into an agreement to co-promote, an innovative oral therapy for the treatment of patients with prostate cancer...
10 October 2013 | By Teva Pharmaceutical Industries Ltd
$2.0 billion in annual cost savings by the end of 2017 including $1.0 billion by the end of 2014...
9 October 2013 | By Pfizer
The brand’s latest innovation provides eight hours of moisture and contains advanced ingredient...
9 October 2013 | By Pfizer Inc.
“We are excited to see progress in our development program in psoriasis..."
9 October 2013 | By Gilead
"We are pleased that idelalisib has shown a clinically meaningful benefit for patients..."
